Literature DB >> 29229664

Metabolic Vulnerabilities of Prostate Cancer: Diagnostic and Therapeutic Opportunities.

Giorgia Zadra1,2, Massimo Loda1,2,3.   

Abstract

Cancer cells hijack metabolic pathways to support bioenergetics and biosynthetic requirements for their uncontrolled growth. Thus, cancer can be considered as a metabolic disease. In this review, we discuss the main metabolic features of prostate cancer with a particular focus on the link between oncogene-directed cancer metabolic regulation, metabolism rewiring, and epigenetic regulation. The potential of using metabolic profiling as a means to predict disease behavior and to identify novel therapeutic targets and new diagnostic markers will be addressed as well as the current challenges in metabolomics analyses. Finally, diagnostic and prognostic metabolic imaging approaches, including positron emission tomography, mass spectrometry, nuclear magnetic resonance, and their translational applications, will be discussed. Here, we emphasize how targeting metabolic vulnerabilities in prostate cancer may pave the way for novel personalized diagnostic and therapeutic interventions.
Copyright © 2018 Cold Spring Harbor Laboratory Press; all rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 29229664      PMCID: PMC6169980          DOI: 10.1101/cshperspect.a030569

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN: 2157-1422            Impact factor:   6.915


  142 in total

1.  Critical role of O-Linked β-N-acetylglucosamine transferase in prostate cancer invasion, angiogenesis, and metastasis.

Authors:  Thomas P Lynch; Christina M Ferrer; S RaElle Jackson; Kristina S Shahriari; Keith Vosseller; Mauricio J Reginato
Journal:  J Biol Chem       Date:  2012-01-24       Impact factor: 5.157

2.  Macronutrients, fatty acids, cholesterol, and risk of benign prostatic hyperplasia.

Authors:  Francesca Bravi; Cristina Bosetti; Luigino Dal Maso; Renato Talamini; Maurizio Montella; Eva Negri; Valerio Ramazzotti; Silvia Franceschi; Carlo La Vecchia
Journal:  Urology       Date:  2006-06       Impact factor: 2.649

Review 3.  MR imaging and MR spectroscopic imaging in the pre-treatment evaluation of prostate cancer.

Authors:  H Hricak
Journal:  Br J Radiol       Date:  2005       Impact factor: 3.039

4.  Metabolomic signatures of aggressive prostate cancer.

Authors:  Jonathan E McDunn; Zhen Li; Klaus-Peter Adam; Bruce P Neri; Robert L Wolfert; Michael V Milburn; Yair Lotan; Thomas M Wheeler
Journal:  Prostate       Date:  2013-07-03       Impact factor: 4.104

5.  mRNA expression signature of Gleason grade predicts lethal prostate cancer.

Authors:  Kathryn L Penney; Jennifer A Sinnott; Katja Fall; Yudi Pawitan; Yujin Hoshida; Peter Kraft; Jennifer R Stark; Michelangelo Fiorentino; Sven Perner; Stephen Finn; Stefano Calza; Richard Flavin; Matthew L Freedman; Sunita Setlur; Howard D Sesso; Swen-Olof Andersson; Neil Martin; Philip W Kantoff; Jan-Erik Johansson; Hans-Olov Adami; Mark A Rubin; Massimo Loda; Todd R Golub; Ove Andrén; Meir J Stampfer; Lorelei A Mucci
Journal:  J Clin Oncol       Date:  2011-05-02       Impact factor: 44.544

6.  FDG PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation.

Authors:  N Oyama; H Akino; Y Suzuki; H Kanamaru; H Ishida; K Tanase; N Sadato; Y Yonekura; K Okada
Journal:  Nucl Med Commun       Date:  2001-09       Impact factor: 1.690

Review 7.  Metabolomic Biomarkers of Prostate Cancer: Prediction, Diagnosis, Progression, Prognosis, and Recurrence.

Authors:  Rachel S Kelly; Matthew G Vander Heiden; Edward Giovannucci; Lorelei A Mucci
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-04-06       Impact factor: 4.254

8.  Cancer cells incorporate and remodel exogenous palmitate into structural and oncogenic signaling lipids.

Authors:  Sharon M Louie; Lindsay S Roberts; Melinda M Mulvihill; Kunxin Luo; Daniel K Nomura
Journal:  Biochim Biophys Acta       Date:  2013-07-19

9.  Integrative clinical genomics of advanced prostate cancer.

Authors:  Dan Robinson; Eliezer M Van Allen; Yi-Mi Wu; Nikolaus Schultz; Robert J Lonigro; Juan-Miguel Mosquera; Bruce Montgomery; Mary-Ellen Taplin; Colin C Pritchard; Gerhardt Attard; Himisha Beltran; Wassim Abida; Robert K Bradley; Jake Vinson; Xuhong Cao; Pankaj Vats; Lakshmi P Kunju; Maha Hussain; Felix Y Feng; Scott A Tomlins; Kathleen A Cooney; David C Smith; Christine Brennan; Javed Siddiqui; Rohit Mehra; Yu Chen; Dana E Rathkopf; Michael J Morris; Stephen B Solomon; Jeremy C Durack; Victor E Reuter; Anuradha Gopalan; Jianjiong Gao; Massimo Loda; Rosina T Lis; Michaela Bowden; Stephen P Balk; Glenn Gaviola; Carrie Sougnez; Manaswi Gupta; Evan Y Yu; Elahe A Mostaghel; Heather H Cheng; Hyojeong Mulcahy; Lawrence D True; Stephen R Plymate; Heidi Dvinge; Roberta Ferraldeschi; Penny Flohr; Susana Miranda; Zafeiris Zafeiriou; Nina Tunariu; Joaquin Mateo; Raquel Perez-Lopez; Francesca Demichelis; Brian D Robinson; Marc Schiffman; David M Nanus; Scott T Tagawa; Alexandros Sigaras; Kenneth W Eng; Olivier Elemento; Andrea Sboner; Elisabeth I Heath; Howard I Scher; Kenneth J Pienta; Philip Kantoff; Johann S de Bono; Mark A Rubin; Peter S Nelson; Levi A Garraway; Charles L Sawyers; Arul M Chinnaiyan
Journal:  Cell       Date:  2015-05-21       Impact factor: 41.582

Review 10.  Metabolomics by numbers: acquiring and understanding global metabolite data.

Authors:  Royston Goodacre; Seetharaman Vaidyanathan; Warwick B Dunn; George G Harrigan; Douglas B Kell
Journal:  Trends Biotechnol       Date:  2004-05       Impact factor: 19.536

View more
  18 in total

Review 1.  Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention.

Authors:  Lisa M Butler; Ylenia Perone; Jonas Dehairs; Leslie E Lupien; Vincent de Laat; Ali Talebi; Massimo Loda; William B Kinlaw; Johannes V Swinnen
Journal:  Adv Drug Deliv Rev       Date:  2020-07-23       Impact factor: 15.470

Review 2.  Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Medicines (Basel)       Date:  2019-07-30

Review 3.  Is Mitochondrial Dysfunction a Common Root of Noncommunicable Chronic Diseases?

Authors:  Alexis Diaz-Vegas; Pablo Sanchez-Aguilera; James R Krycer; Pablo E Morales; Matías Monsalves-Alvarez; Mariana Cifuentes; Beverly A Rothermel; Sergio Lavandero
Journal:  Endocr Rev       Date:  2020-06-01       Impact factor: 19.871

Review 4.  Tumour fatty acid metabolism in the context of therapy resistance and obesity.

Authors:  Andrew J Hoy; Shilpa R Nagarajan; Lisa M Butler
Journal:  Nat Rev Cancer       Date:  2021-08-20       Impact factor: 60.716

5.  Deregulation of Cholesterol Homeostasis by a Nuclear Hormone Receptor Crosstalk in Advanced Prostate Cancer.

Authors:  Nianxin Yang; Yatian Yang; Zenghong Huang; Hong-Wu Chen
Journal:  Cancers (Basel)       Date:  2022-06-24       Impact factor: 6.575

Review 6.  Tumour metabolism and its unique properties in prostate adenocarcinoma.

Authors:  David A Bader; Sean E McGuire
Journal:  Nat Rev Urol       Date:  2020-02-28       Impact factor: 14.432

7.  Metabolomics of Prostate Cancer Gleason Score in Tumor Tissue and Serum.

Authors:  Kathryn L Penney; Svitlana Tyekucheva; Jacob Rosenthal; Habiba El Fandy; Ryan Carelli; Stephanie Borgstein; Giorgia Zadra; Giuseppe Nicolò Fanelli; Lavinia Stefanizzi; Francesca Giunchi; Mark Pomerantz; Samuel Peisch; Hannah Coulson; Rosina Lis; Adam S Kibel; Michelangelo Fiorentino; Renato Umeton; Massimo Loda
Journal:  Mol Cancer Res       Date:  2020-11-09       Impact factor: 5.852

8.  Human DECR1 is an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosis.

Authors:  Zeyad D Nassar; Chui Yan Mah; Jonas Dehairs; Ingrid Jg Burvenich; Swati Irani; Margaret M Centenera; Madison Helm; Raj K Shrestha; Max Moldovan; Anthony S Don; Jeff Holst; Andrew M Scott; Lisa G Horvath; David J Lynn; Luke A Selth; Andrew J Hoy; Johannes V Swinnen; Lisa M Butler
Journal:  Elife       Date:  2020-07-20       Impact factor: 8.140

9.  High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program.

Authors:  David P Labbé; Giorgia Zadra; Meng Yang; Jaime M Reyes; Charles Y Lin; Stefano Cacciatore; Ericka M Ebot; Amanda L Creech; Francesca Giunchi; Michelangelo Fiorentino; Habiba Elfandy; Sudeepa Syamala; Edward D Karoly; Mohammed Alshalalfa; Nicholas Erho; Ashley Ross; Edward M Schaeffer; Ewan A Gibb; Mandeep Takhar; Robert B Den; Jonathan Lehrer; R Jeffrey Karnes; Stephen J Freedland; Elai Davicioni; Daniel E Spratt; Leigh Ellis; Jacob D Jaffe; Anthony V DʼAmico; Philip W Kantoff; James E Bradner; Lorelei A Mucci; Jorge E Chavarro; Massimo Loda; Myles Brown
Journal:  Nat Commun       Date:  2019-09-25       Impact factor: 14.919

10.  Three-dimensional nuclear magnetic resonance spectroscopy: a complementary tool to multiparametric magnetic resonance imaging in the identification of aggressive prostate cancer at 3.0T.

Authors:  Michael Deal; Florian Bardet; Paul-Michael Walker; Mathilde Funes de la Vega; Alexandre Cochet; Luc Cormier; Imad Bentellis; Romaric Loffroy
Journal:  Quant Imaging Med Surg       Date:  2021-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.